An open-label, sequential-group, dose-escalation phase I clinical trial of CLR 131 Pediatric Cancers.

Trial Profile

An open-label, sequential-group, dose-escalation phase I clinical trial of CLR 131 Pediatric Cancers.

Planning
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2017

At a glance

  • Drugs CLR 1404 I-131 (Primary)
  • Indications Brain cancer; Hodgkin's disease; Lymphoma; Neuroblastoma; Sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Dec 2017 New trial record
    • 14 Dec 2017 According to a Cellectar Biosciences media release, the study will be initiated with the pediatric oncologists and Nuclear Medicine/Radiology Group at The University of Wisconsin Carbone Cancer Center.
    • 14 Dec 2017 According to a Cellectar Biosciences media release, the company has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for this study of CLR 131 in children and adolescents with select rare and orphan designated cancers.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top